tetano
Editor, Senior Moderator
Antibodies (Basel). 2019 Feb 10;8(1). pii: E14. doi: 10.3390/antib8010014.
[h=1]Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin.[/h] Ramage W[SUP]1[/SUP], Gaiotto T[SUP]2[/SUP], Ball C[SUP]3[/SUP], Risley P[SUP]4[/SUP], Carnell GW[SUP]5[/SUP], Temperton N[SUP]6[/SUP], Cheung CY[SUP]7[/SUP], Engelhardt OG[SUP]8[/SUP], Hufton SE[SUP]9[/SUP].
[h=3]Author information[/h] 1 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. walter.ramage@nibsc.org. 2 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. Tiziano.Gaiotto@gmail.com. 3 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. chris.ball@nibsc.org. 4 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. paul.risley@nibsc.org. 5 Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK. g.carnell@gmail.com. 6 Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK. n.temperton@kent.ac.uk. 7 Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. chung.cheung@hli.ubc.ca. 8 Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. othmar.engelhardt@nibsc.org. 9 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. simon.hufton@nibsc.org.
[h=3]Abstract[/h] Influenza B virus (IBV) circulates in the human population and causes considerable disease burden worldwide, each year. Current IBV vaccines can struggle to mount an effective cross-reactive immune response, as strains become mismatched, due to constant antigenic changes. Additional strategies which use monoclonal antibodies, with broad reactivity, are of considerable interest, both, as diagnostics and as immunotherapeutics. Alternatives to conventional monoclonal antibodies, such as single domain antibodies (Nanobodies[SUP]TM[/SUP]) with well-documented advantages for applications in infectious disease, have been emerging. In this study we have isolated single domain antibodies (sdAbs), specific to IBV, using alpacas immunised with recombinant hemagglutinin (HA) from two representative viruses, B/Florida/04/2006 (B/Yamagata lineage) and B/Brisbane/60/2008 (B/Victoria lineage). Using phage display, we have isolated a panel of single domain antibodies (sdAbs), with both cross-reactive and lineage-specific binding. Several sdAbs recognise whole virus antigens, corresponding to influenza B strains included in vaccines spanning over 20 years, and were capable of neutralising IBV pseudotypes corresponding to prototype strains from both lineages. Lineage-specific sdAbs recognised the head domain, whereas, sdAbs identified as cross-reactive could be classified as either head binding or stem binding. Using yeast display, we were able to correlate lineage specificity with naturally occurring sequence divergence, at residue 122 in the highly variable 120 loop of the HA1 domain. The single domain antibodies described, might have applications in IBV diagnostics, vaccine potency testing and as immunotherapeutics.
[h=4]KEYWORDS:[/h] NanobodyTM; epitope mapping; hemagglutinin; influenza; influenza B virus; phage display; single domain antibody; yeast display
PMID: 31544820 DOI: 10.3390/antib8010014
[h=1]Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin.[/h] Ramage W[SUP]1[/SUP], Gaiotto T[SUP]2[/SUP], Ball C[SUP]3[/SUP], Risley P[SUP]4[/SUP], Carnell GW[SUP]5[/SUP], Temperton N[SUP]6[/SUP], Cheung CY[SUP]7[/SUP], Engelhardt OG[SUP]8[/SUP], Hufton SE[SUP]9[/SUP].
[h=3]Author information[/h] 1 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. walter.ramage@nibsc.org. 2 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. Tiziano.Gaiotto@gmail.com. 3 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. chris.ball@nibsc.org. 4 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. paul.risley@nibsc.org. 5 Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK. g.carnell@gmail.com. 6 Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK. n.temperton@kent.ac.uk. 7 Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. chung.cheung@hli.ubc.ca. 8 Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. othmar.engelhardt@nibsc.org. 9 Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. simon.hufton@nibsc.org.
[h=3]Abstract[/h] Influenza B virus (IBV) circulates in the human population and causes considerable disease burden worldwide, each year. Current IBV vaccines can struggle to mount an effective cross-reactive immune response, as strains become mismatched, due to constant antigenic changes. Additional strategies which use monoclonal antibodies, with broad reactivity, are of considerable interest, both, as diagnostics and as immunotherapeutics. Alternatives to conventional monoclonal antibodies, such as single domain antibodies (Nanobodies[SUP]TM[/SUP]) with well-documented advantages for applications in infectious disease, have been emerging. In this study we have isolated single domain antibodies (sdAbs), specific to IBV, using alpacas immunised with recombinant hemagglutinin (HA) from two representative viruses, B/Florida/04/2006 (B/Yamagata lineage) and B/Brisbane/60/2008 (B/Victoria lineage). Using phage display, we have isolated a panel of single domain antibodies (sdAbs), with both cross-reactive and lineage-specific binding. Several sdAbs recognise whole virus antigens, corresponding to influenza B strains included in vaccines spanning over 20 years, and were capable of neutralising IBV pseudotypes corresponding to prototype strains from both lineages. Lineage-specific sdAbs recognised the head domain, whereas, sdAbs identified as cross-reactive could be classified as either head binding or stem binding. Using yeast display, we were able to correlate lineage specificity with naturally occurring sequence divergence, at residue 122 in the highly variable 120 loop of the HA1 domain. The single domain antibodies described, might have applications in IBV diagnostics, vaccine potency testing and as immunotherapeutics.
[h=4]KEYWORDS:[/h] NanobodyTM; epitope mapping; hemagglutinin; influenza; influenza B virus; phage display; single domain antibody; yeast display
PMID: 31544820 DOI: 10.3390/antib8010014